Antiandrogen Monotherapy for mCRPC

preview_player
Показать описание
In this segment, the panelists discuss the evolution of treatment for mCRPC, and the use of newer anti-androgen medications as monotherapy.

  1. OncLive
  2. cancer
  3. oncology
  4. Antiandrogen (Drug Class)
  5. Prostate Cancer (Disease Or Medical Condition)
  6. Medicine (Field Of Study)
Рекомендации по теме
Antiandrogen Monotherapy for 0:04:48

Antiandrogen Monotherapy for mCRPC

M2 - Evolving 0:04:02

M2 - Evolving landscape of PARP inhibitors in mCRPC: combination with anti-androgens

Anti-Androgen Trials 0:12:24

Anti-Androgen Trials

Dr. Choudhury on 0:01:45

Dr. Choudhury on Antiandrogen Treatment Selection in Nonmetastatic CRPC

What changes do 0:01:01

What changes do you see happening in anti-androgen therapy for prostate cancer?

Antiandrogens—Differences and Sequencing 0:04:58

Antiandrogens—Differences and Sequencing

What Changes Are 0:02:12

What Changes Are Happening in Anti Androgen Therapy?

Six Androgen Deprivation 0:07:54

Six Androgen Deprivation Therapy options - Dr. Michael McKenzie

USMLE ANTIANDROGEN DRUGS 0:10:53

USMLE ANTIANDROGEN DRUGS

Differing Perspectives on 0:07:04

Differing Perspectives on Anti-Androgen Therapy - EAU 15

New Concepts in 0:27:50

New Concepts in ADT

PEACE-3 Study ESMO 0:02:57

PEACE-3 Study ESMO 2024 - Combining Enzalutamide + Radium-223 in mCRPC

ADT is the 0:35:48

ADT is the Building Block for Advanced Prostate Cancer Therapy

Treating mCRPC with 0:08:09

Treating mCRPC with Newer Hormonal Agents

A Phase II 0:02:04

A Phase II trial investigating neoadjuvant abiraterone and cabazitaxel in high-risk prostate cancer

EAU 2023:Optimal Treatment 0:21:39

EAU 2023:Optimal Treatment Sequencing in the Area of Triplet Therapies for Hormone-SensitiveDisease

Emerging treatments for 0:04:34

Emerging treatments for mCRPC

Elahe Mostaghel - 0:47:22

Elahe Mostaghel - Resistance to AR Signaling Inhibitors in Castration Resistant Prostate Cancer

Dr. Chi on 0:01:34

Dr. Chi on Abiraterone Versus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer

TERRAIN: Enzalutamide versus 0:01:30

TERRAIN: Enzalutamide versus bicalutamide for metastatic prostate cancer

Redefining mCRPC - 0:31:24

Redefining mCRPC - The Androgen Receptor (AR) Singnaling Axis and AR-directed therapies

Multidisciplinary Approach to 0:11:37

Multidisciplinary Approach to mCRPC Treatment

TALAPRO-2 Phase III 0:05:21

TALAPRO-2 Phase III study design

Dr. Richard Lam, 1:33:13

Dr. Richard Lam, IPCSG November 2019 ADT, The latest updates